Research & Development
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Company hopes a different formulation of its intracanicular insert of cyclosporin might provide longer duration of drug in the eye and better tear production with it.
The company announced it would withdraw the BLA for balstilimab monotherapy in cervical cancer following Keytruda’s full approval, but it plans to keep developing the drug.
The French major and partner Regeneron expect to file Dupixent for the rare skin disease next year after a Phase III trial of the blockbuster hit its primary and secondary endpoints.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.
With Phase III data showing non-inferiority to colistin, as well as nephrotoxicity superiority, Entasis thinks sulbactam/durlobactam will provide a new standard of care and succeed where Achaogen’s Zemdri failed.
The companies will seek approval for zuranolone in MDD second-half 2022 and in PPD in first-half 2023, but that also means launch will probably happen second-half 2023.
The formal split between the companies had been in the works since January, with 2seventy set to take over oncology operations while bluebird focuses on gene therapies.
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Oxford BioMedica aim to get their CFTR gene therapy into the clinic soon, confident it could offer a long-lasting option for patients with cystic fibrosis.
The drug showed favorable but not significant trends across secondary endpoints, and greater efficacy in slower-progressing patients and those treated earlier in the disease, in a small subpopulation.
EyeGene R&D head talks to Scrip at CPhI Korea about the development of its COVID-19 vaccine candidate EG-COVID, potential challenges in clinical trials and positioning and the over-riding importance of validating a viable mRNA platform.
In this week's podcast edition of Five Must-Know Things: US tax policies challenge pharma; J&J’s long-time R&D head to retire; Legend Biotech’s CEO talks about plans; BMS disappointment in ulcerative colitis; and another gene therapy partnership for Takeda.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.